Net-Debt-Free Pharma Stock Targets Rs 1,000 Crore Revenue in Three Years, Aims for 15–18% Annual Growth
எங்களுடன் சேருங்கள்
எங்களைப் பின்தொடரவும்
It expects demand across the cardiac, diabetic, dermatology and ENT segments to contribute to this growth. While the company has an established presence in acute therapies, it is also developing its portfolio in lifestyle and chronic treatments, particularly women's healthcare and dermatology.
✨ முக்கிய குறிப்புகள்
Lincoln Pharmaceuticals Limited reported a 20.52 per cent YoY increase in consolidated net profit to Rs 57.50 crore for the first half of FY27, compared with Rs 47.71 crore in the corresponding period last year. Total income rose 18.39 per cent to Rs 402.43 crore from Rs 339.93 crore, while EBITDA increased 18.37 per cent to Rs 84.92 crore from Rs 71.74 crore. Earnings per share (EPS) stood at Rs 28.29, against Rs 23.79 in H1 FY26.
For the quarter ended September 2026 (Q2 FY27), the company reported a consolidated net profit of Rs 20.84 crore, up 4.15 per cent from Rs 20.01 crore in the same quarter last year. Total income increased 17.75 per cent to Rs 200.88 crore from Rs 170.60 crore. However, EBITDA grew at a slower pace of 1.71% to Rs 33.22 crore, compared with Rs 32.66 crore in Q2 FY26. Quarterly EPS stood at Rs 10.20, against Rs 9.98 a year ago.
Alongside its financial performance, Lincoln Pharmaceuticals has been expanding its presence in the domestic pharmaceutical market. During FY26, the company introduced four new divisions and expanded its manufacturing capabilities at the Khatraj plant in Gujarat, including the addition of an Active Pharmaceutical Ingredient (API) facility. The expansion is part of its efforts to strengthen production capabilities and support its growing product portfolio.
Looking ahead, the company has set a revenue target of Rs 1,000 crore over the next three years, with an expected annual growth rate of 15-18 per cent. It expects demand across the cardiac, diabetic, dermatology and ENT segments to contribute to this growth. While the company has an established presence in acute therapies, it is also developing its portfolio in lifestyle and chronic treatments, particularly women's healthcare and dermatology.
International markets remain another area of expansion. Lincoln Pharmaceuticals currently exports its products to more than 60 countries across Africa, the Americas and Southeast Asia, and plans to extend its reach to 90 countries over the next two to three years. Its recent entry into Canada, along with TGA Australia and EU GMP approvals, forms part of its plans to strengthen its presence in regulated and semi-regulated markets.
The company has developed more than 600 formulations across 15 therapeutic areas. Its portfolio includes over 1,700 registered products, with another 700 under development. It has also filed more than 25 patent applications and has been granted seven patents.
On the operational front, Lincoln Pharmaceuticals stated that nearly 100 per cent of its energy requirements are met through renewable sources, supported by its wind and Solar power projects. The company remains net-debt free, while foreign institutional investors held a 4.55 per cent stake as of September 30, 2026.
Meanwhile, shareholders approved a Dividend of Rs 1.80 per equity share for FY26 at the company's 32nd Annual General Meeting held on September 30, 2026.
Disclaimer: The article is for informational purposes only and not investment advice.